Screener
Prime Medicine PRME Restricted Cash
Restricted Cash at other companies
Other financials
Where this comes from
Reported directly by Prime Medicine in its filing.
Tagged under the XBRL concept us-gaap:RestrictedCash.
The source filing: Prime Medicine’s 10-Q, filed August 6, 2026. Open the filing →
- Filed
- Aug 6, 2026, 8:03 AM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001628280-26-053883
FAQ
- What is Prime Medicine's restricted cash?
- Prime Medicine (PRME) reported restricted cash of $13.69M in Q2 2026.
- How has Prime Medicine's restricted cash changed year-over-year?
- Prime Medicine's restricted cash decreased by 0.0% year-over-year, from $13.69M to $13.69M.
- What is the long-term trend for Prime Medicine's restricted cash?
- Over 4 years (2021 to 2025), Prime Medicine's restricted cash has grown at a 1.1% compound annual growth rate (CAGR), from $13.13M to $13.69M.
- What does restricted cash mean?
- Cash restricted for specific purposes by contractual, regulatory, or legal requirements — not available for general corporate use.
Ask your AI about Prime Medicine's restricted cash.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude